<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141775</url>
  </required_header>
  <id_info>
    <org_study_id>IBIS</org_study_id>
    <nct_id>NCT03141775</nct_id>
  </id_info>
  <brief_title>Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)</brief_title>
  <acronym>IBIS</acronym>
  <official_title>Incidence and Economic Burden of Community and Hospital- Acquired Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBIS is a prospective, observational study, which aims to assess the cost of CDI per day,
      hospitalization and year including description of incremental costs in hospitalized patients,
      and recurrent episodes, in German hospitals. Exposure to CDI drugs will not be influenced and
      remains at the discretion of the treating physician.

      In addition to treatment, Health-related quality of life (HRQL) will be analyzed using
      standardized questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Documentation of patient is performed by using the web-based survey platform
      www.ClinicalSurveys.net which was set up by researchers of the University Hospital of
      Cologne. This survey platform enables an optimal performance in epidemiological,
      observational, and interventional trials and is characterized by layered access security and
      frequent data backup. It has been used for numerous registry and cohort studies with approval
      of competent authorities and ethics boards.

      The following two differences of data documentation are observed:

        1. Retrospective data documentation:

           Data of patients that are too sick to provide informed consent, (up to 30% of all
           patients enrolled) will be obtained retrospectively, at least 90 days after diagnosis
           and will be documented in an anonymized fashion. For these patients, documentation of
           HRQL will not be feasible.

        2. Prospective data documentation:

      Data of patients with an informed consent.

      The following data items are retrospectively or prospectively documented into our database,
      depending on if a informed consent exists or not:

        -  Demography: age (yrs), gender (m/f), comorbidities (as categories)

        -  Charlson Comorbidity Index (CCI)

        -  Karnofsky Score (0-100%)

        -  APACHE Score for patients in ICU

        -  Number of hospitalizations in the past 12 months prior to the CDI index episode

        -  Type and duration of antibiotic treatment during the last 3 months

        -  Diagnostic measures (microbiological tests, imaging, endoscopy) leading to diagnosis of
           CDI

        -  Severe and/or complicated CDI (Severe: white blood cell count ≥15 × 10³/μL and/or an
           increase in creatinine ≥1.5 times the baseline level; complicated: at least 1 of the
           following: hypotension requiring vasopressors, ICU admission for a complication of CDI,
           ileus leading to installation of a nasogastric tube, toxic megacolon, colonic
           perforation, or colectomy)

        -  Bowel movements: frequency and consistence according to Bristol stool scale (see
           appendix 1)

        -  Treatment for CDI: substance, dosage, frequency, duration

        -  Other antibiotic treatment: substance, dosage, frequency, duration

        -  Diagnosis of CDI recurrence: time point, diagnostic measures

        -  Treatment of CDI recurrence: substance, dosage, frequency, duration

        -  Duration of hospitalization: overall, types (general, intermediate care, intensive care,
           bone marrow transplantation)

        -  Mechanical ventilation (y/n)

        -  Days with contact isolation

        -  Days in single room

        -  Adverse drug reactions

        -  Health-related quality of life (HRQL) as determined by Garey et al. J Clin Gastroenterol
           2016 (for prospective analysis only)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the cost of CDI index and recurrent episodes in German hospitals</measure>
    <time_frame>90 days</time_frame>
    <description>Analyse direct and indirect costs associated with CDI per day, hospitalization and year including description of incremental costs in hospitalized patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of health-related quality of life (HRQL)</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment of quality of life of patients with an CDI episode using a QoL questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">541</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile Diarrhea</condition>
  <arm_group>
    <arm_group_label>Treatment of CDI</arm_group_label>
    <description>Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of CDI</intervention_name>
    <description>Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea</description>
    <arm_group_label>Treatment of CDI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with a CDI episode in German hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Index episode of CDI based on

               -  the presence of diarrhea (defined as ≥3 unformed bowel movements/24h) plus

               -  an enzyme immunoassay (EIA) detecting Glutamate dehydrogenase (GDH) or polymerase
                  chain reaction (PCR) for toxin B test plus

               -  a positive EIA for toxin A and B

          -  Ongoing or new hospitalization at inclusion into the study.

          -  Written informed consent (IC) has been obtained from the study subject or a legal
             representative.

        Exclusion Criteria:

          -  Patient with any social or logistical condition which in the opinion of the
             investigator may interfere with the conduct of the study, such as incapacity to well
             understand, not willing to collaborate, or cannot easily be contacted after discharge.

          -  CDI episode within the previous 84 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Vehreschild, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne, Department of Internal Medicine / Infectious Diseases, Cologne, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Vehreschild, MD</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>88794</phone_ext>
    <email>maria.vehreschild@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Städtisches Klinikum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meinolf Karthaus, Prof</last_name>
      <phone>+49 89 6210</phone>
      <phone_ext>5245</phone_ext>
      <email>meinolf.karthaus@klinikum-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Schalk, MD</last_name>
      <email>Enrico.Schalk@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Reuken, MD</last_name>
      <phone>+49 3641 93</phone>
      <phone_ext>24504</phone_ext>
      <email>philipp.reuken@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vehreschild, MD</last_name>
      <phone>+49 221 478 88794</phone>
      <email>maria.vehreschild@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Porz am Rhein</name>
      <address>
        <city>Cologne</city>
        <zip>51149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Holtmeier, Prof</last_name>
      <phone>+492203/566</phone>
      <phone_ext>1326</phone_ext>
      <email>W.Holtmeier@khporz.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Pützfeld, MD</last_name>
      <email>s.puetzfeld@khporz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schmiedel, MD</last_name>
      <email>s.schmiedel@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Vehreschild MJ, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Töx U, Wisplinghoff H, Von Bergwelt-Baildon M, Cornely OA, Vehreschild JJ. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant. 2014 Jun;20(6):823-8. doi: 10.1016/j.bbmt.2014.02.022. Epub 2014 Mar 6.</citation>
    <PMID>24607558</PMID>
  </reference>
  <reference>
    <citation>Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011 Jan 1;377(9759):63-73. doi: 10.1016/S0140-6736(10)61266-4.</citation>
    <PMID>21084111</PMID>
  </reference>
  <reference>
    <citation>Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis. 2013 Apr;56(8):1108-16. doi: 10.1093/cid/cis1209. Epub 2013 Jan 8.</citation>
    <PMID>23300235</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Maria J.G.T. Vehreschild</investigator_full_name>
    <investigator_title>PD MD</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile associated diarrhea (CDAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

